Literature DB >> 30498951

Disease duration in E200K familial Creutzfeldt-Jakob disease is correlated with clinical, radiological, and laboratory variables.

Oren S Cohen1,2, Joab Chapman3,4,5, Amos D Korczyn3, Zeev Nitsan6, Shmuel Appel6, Esther Kahana6, Hanna Rosenmann7, Chen Hoffmann3,8.   

Abstract

Previous studies have suggested that disease duration in Creutzfeldt-Jakob disease (CJD) may be related to the radiological findings or cerebrospinal fluid (CSF) tau levels; however, it is not yet established whether clinical, radiological, and laboratory findings at diagnosis can predict survival or have a prognostic value. The aim of this study was to examine whether the disease duration is correlated with clinical, radiological, and laboratory variables. The study population consisted of consecutive familial CJD (fCJD) patients that were assessed within 1 week from the diagnosis including the CJD neurological scale (CJD-NS), Minimental Status Examination, Frontal Assessment Battery, NIH Stroke Scale, and the expanded disability status scale. In addition, a single MRI study was done and measurements of the extent of the cortical and subcortical involvement were performed. CSF was examined as part of the workout, and tau levels were determined. Sixty-nine fCJD patients were included in the study (43 males, mean age 59.3 ± 8.4, range 44-79 years). The mean disease duration was 7.3 ± 6.9 months (median 5.6 months, range 2-20 months). A significant correlation was found between the disease duration and the CJD-NS, the disease burden as reflected by the degree of cortical involvement by DWI, and the CSF tau levels. The findings of the current study reveal that several findings at disease onset including the disease severity, the cortical changes, and the tau levels are each individually correlated with disease duration and can be used by the clinician as a tool to predict the disease course and prognosis.

Entities:  

Keywords:  CSF; Creutzfeldt–Jakob disease; E200K mutation; Neuroimaging; Prognosis; Tau

Mesh:

Substances:

Year:  2018        PMID: 30498951     DOI: 10.1007/s00702-018-1958-1

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  26 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease.

Authors:  M Otto; J Wiltfang; L Cepek; M Neumann; B Mollenhauer; P Steinacker; B Ciesielczyk; W Schulz-Schaeffer; H A Kretzschmar; S Poser
Journal:  Neurology       Date:  2002-01-22       Impact factor: 9.910

3.  Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis.

Authors:  Geoffrey S Young; Michael D Geschwind; Nancy J Fischbein; Jennifer L Martindale; Roland G Henry; Songling Liu; Ying Lu; Stephen Wong; Hong Liu; Bruce L Miller; William P Dillon
Journal:  AJNR Am J Neuroradiol       Date:  2005 Jun-Jul       Impact factor: 3.825

Review 4.  Molecular biology of prion diseases.

Authors:  S B Prusiner
Journal:  Science       Date:  1991-06-14       Impact factor: 47.728

5.  Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease.

Authors:  M S Palmer; A J Dryden; J T Hughes; J Collinge
Journal:  Nature       Date:  1991-07-25       Impact factor: 49.962

6.  The FAB: a Frontal Assessment Battery at bedside.

Authors:  B Dubois; A Slachevsky; I Litvan; B Pillon
Journal:  Neurology       Date:  2000-12-12       Impact factor: 9.910

7.  The imaging appearance of Creutzfeldt-Jakob disease caused by the E200K mutation.

Authors:  Robert K Fulbright; Peter B Kingsley; Xiaodong Guo; Chen Hoffmann; Esther Kahana; Joab C Chapman; Isak Prohovnik
Journal:  Magn Reson Imaging       Date:  2006-09-07       Impact factor: 2.546

8.  A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease.

Authors:  B Van Everbroeck; S Quoilin; J Boons; J J Martin; P Cras
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

9.  Molecular classification of sporadic Creutzfeldt-Jakob disease.

Authors:  Andrew F Hill; Susan Joiner; Jonathan D F Wadsworth; Katie C L Sidle; Jeanne E Bell; Herbert Budka; James W Ironside; John Collinge
Journal:  Brain       Date:  2003-06       Impact factor: 13.501

10.  Brain-derived proteins in the CSF: do they correlate with brain pathology in CJD?

Authors:  Constanze Boesenberg-Grosse; Walter J Schulz-Schaeffer; Monika Bodemer; Barbara Ciesielczyk; Bettina Meissner; Anna Krasnianski; Mario Bartl; Uta Heinemann; Daniela Varges; Sabina Eigenbrod; Hans A Kretzschmar; Alison Green; Inga Zerr
Journal:  BMC Neurol       Date:  2006-09-21       Impact factor: 2.474

View more
  1 in total

1.  Report of a Case of Creutzfeldt-Jakob Disease With an Unusual Quick Evolution.

Authors:  Hajar Fadili; Rim Tazi; Hiba El Oury; Karim El Aidaoui; Asmaa Hazim
Journal:  Cureus       Date:  2022-03-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.